|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
Three of the four tumors had a BRAF (V600E) driver mutation, an EGFR (del E746-T751/S752V) driver mutation, or driver mutations in both EGFR (E709G) and KRAS (G12V).
|
29624782 |
2018 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
In conclusion, whilst oncogenic KRAS mutation might activate Yap in other cell types, we could find no evidence for this in myoblasts because the expression of KRAS G12V expression did not change Yap/Taz activity in myoblasts and there was a limited overlap in gene expression between KRAS G12V and YAP1 S127A-driven tumours.
|
30353028 |
2018 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
In combination with p53 silencing, KRAS(G12V) alone was sufficient to fully transform the immortalized HPDECs, and MYC markedly accelerated the development of tumors.
|
24858378 |
2014 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
The introduction in different orders of the oncogenic allele of Ras (H-Ras(G12V)) and the mutant p53(DD) that disrupts the p53 pathway yielded tumors displaying major differences in histological features, tumorigenicity, and metastatic behavior.
|
22589739 |
2012 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
In contrast, the combination of p53 RNAi knockdown with expression of oncogenic H-Ras(G12V) transformed the p16-deficient BAR-T cells, as evidenced by their loss of contact inhibition, by their formation of colonies in soft agar, and by their generation of tumors in immunodeficient mice.
|
20927195 |
2010 |
|
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Transcriptional profiling of Kras(G12V)-driven mouse hyperplasias revealed intertumor diversity with a subset that exhibited an aggressive transcriptional profile analogous to that of advanced human adenocarcinomas.
|
26855149 |
2016 |
|
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Firstly, lentivirus-mediated transduction of KRAS(G12V), MYC and human papillomavirus 16 (HPV16) E6/E7 under the control of a tetracyclin-inducible promoter efficiently immortalized and transformed primary HPDECs, which gave rise to adenocarcinomas subcutaneously in an immune-deficient mouse xenograft model, depending on expression of the four genes.
|
24858378 |
2014 |
|
Immunologic Deficiency Syndromes
|
|
0.020 |
GeneticVariation
|
BEFREE |
In contrast, the combination of p53 RNAi knockdown with expression of oncogenic H-Ras(G12V) transformed the p16-deficient BAR-T cells, as evidenced by their loss of contact inhibition, by their formation of colonies in soft agar, and by their generation of tumors in immunodeficient mice.
|
20927195 |
2010 |
|
Immunologic Deficiency Syndromes
|
|
0.020 |
GeneticVariation
|
BEFREE |
We show here that the expression of K-ras(G12V) oncogene in a near diploid HPV16-E6E7 gene immortalized human pancreatic duct epithelial cell line originally derived from normal pancreas induced the formation of carcinoma in 50% of severe combined immunodeficient mice implanted with these cells.
|
15958547 |
2005 |
|
Malignant neoplasm of pancreas
|
|
0.010 |
GeneticVariation
|
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
|
Childhood Embryonal Rhabdomyosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
|
30353028 |
2018 |
|
Embryonal Rhabdomyosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
|
30353028 |
2018 |
|
Rhabdomyosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
First, to compare YAP1 S127A and KRAS G12V-driven rhabdomyosarcomas, we re-analysed gene expression microarray datasets from mouse rhabdomyosarcomas caused by these genes.
|
30353028 |
2018 |
|
Carcinoma, Signet Ring Cell
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DNA sequencing of the 2 microdissected neoplastic components (adenomatous and SRCC) showed the same G12V KRAS mutation.
|
26997454 |
2016 |
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Co-expression of Nm23H1 but not H2 in NIH3T3 cells effectively suppressed neoplastic transformation and tumorigenesis induced by the oncogenic H-Ras G12V mutant.
|
25748386 |
2015 |
|
Stomach Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
One case had a KRAS G12V (c.35G>T) mutation in both the primary gastric tumor and a post-imatinib recurrence.
|
25427437 |
2015 |
|
Carcinoma, Spindle-Cell
|
|
0.010 |
GeneticVariation
|
BEFREE |
Combining p53(R273H) with KRAS(G12V) activation caused transformation of MOE into high-grade sarcomatoid carcinoma when xenografted into nude mice.
|
25810107 |
2015 |
|
Benign Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Whereas the successive expression of Ras(G12V) and p53(DD) led to highly malignant tumors with metastatic behavior, reminiscent of those formed after the simultaneous introduction of p53(DD) and Ras(G12V), the reverse sequence gave rise only to benign tumors.
|
22589739 |
2012 |
|
Well Differentiated Oligodendroglioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1.
|
21643842 |
2011 |
|
Childhood Oligodendroglioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1.
|
21643842 |
2011 |
|
oligodendroglioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1.
|
21643842 |
2011 |
|
Malignant neoplasm of esophagus
|
|
0.010 |
GeneticVariation
|
BEFREE |
We developed two mouse models of esophageal cancer by inoculating immunocompetent mice with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS(G12V) and loss of p53.
|
21869822 |
2011 |
|
Esophageal Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We developed two mouse models of esophageal cancer by inoculating immunocompetent mice with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS(G12V) and loss of p53.
|
21869822 |
2011 |